Short Description

ER & PR receptor assays are routinely performed on Breast carcinomas to assess responsiveness to endocrine therapy and prognosis. Her-2 expression shows responsiveness to Herceptin therapy. Reporting through digital images using Visiopharm AI algorithms enhances the sensitivity of the assay.

PreTest Information

Provide a copy of the Histopathology report. Indicate site of biopsy and provide Clinical history.

Detail Description

IMMUNOHISTOCHEMISTRY DIGITAL BREAST CANCER PANEL 3 Test

Breast cancer is one of the most common types of cancer in women across the world. Early detection and accurate diagnosis are crucial for effective treatment and improved patient outcomes. DNA Labs India offers the Immunohistochemistry Digital Breast Cancer Panel 3 test for the diagnosis and management of breast cancer.

Test Cost

The cost of the Immunohistochemistry Digital Breast Cancer Panel 3 test is INR 7000.

Symptoms of Breast Cancer

Breast cancer can present with a variety of symptoms, including:

• A lump or thickening in the breast or underarm
• Changes in breast size or shape
• Nipple discharge or retraction
• Redness or scaling of the breast or nipple
• Swelling or pain in the breast or underarm

However, it is important to note that not all breast lumps are cancerous, and some breast cancers may not present with any symptoms at all. Regular breast exams and mammograms can help with early detection and diagnosis.

Diagnosis of Breast Cancer

The diagnosis of breast cancer typically involves a combination of imaging tests, such as mammography or ultrasound, and biopsy, which involves removing a small sample of tissue for examination under a microscope. The Immunohistochemistry Digital Breast Cancer Panel 3 test is a type of biopsy that uses specialized antibodies to detect specific proteins on the surface of breast cancer cells. This can help with accurate diagnosis and staging of the cancer, as well as guide treatment decisions.

Conclusion

The Immunohistochemistry Digital Breast Cancer Panel 3 test offered by DNA Labs India is a valuable tool for the diagnosis and management of breast cancer. Early detection and accurate diagnosis are crucial for effective treatment and improved patient outcomes. If you are experiencing any symptoms of breast cancer or have concerns about your breast health, speak with your healthcare provider about the appropriate screening and diagnostic tests for you.

ER & PR receptor assays are routinely performed on Breast carcinomas to assess responsiveness to endocrine therapy and prognosis. Her-2 expression shows responsiveness to Herceptin therapy. Reporting through digital images using Visiopharm AI algorithms enhances the sensitivity of the assay.